title: Accumulation of phosphatydilcholine-hydroperoxide in dialysis patients with diabetic nephropathy.
abstract: Plasma lipid peroxidation in noninsulin dependent diabetes mellitus (DM) patients were evaluated in DM patients undergoing hemodialysis (HD) by means of a chemiluminescence-HPLC for the specific determination of phosphatidylcholine hydroperoxide (PCOOH). Thirty-three uremic patients with DM nephropathy, undergoing 12 hours HD a week using polymethylmethacrylate membrane, were studied. Of them 22 DM patients on HD were divided into 2 age and sex matched groups treated and conventional group in order to clarify therapeutic effect of 500 mg alfa-tocopherol and 600 mg probucol daily. Fifty DM patients without end-stage renal disease (ESRD) who were age-, period of diabetes-, and sex-matched, were selected as positive control of the subjects. Plasma PCOOH levels were significantly elevated in both DM patients, while the plasma PCOOH in normal controls were 227.0 +/- 68.7 pmol/ml. Plasma PCOOH levels of DM patients undergoing HD were significantly higher than that of patients without ESRD (1,330.8 +/- 642.7 pmol/ml vs. 756.6 +/- 431.9 pmol/ml, p < 0.025). Partial correlation coefficient of plasma PCOOH level demonstrated PCOOH and period of HD in DM patients were highly significantly positively correlated (p < 0.01), although single session of HD was not found to produce significantly increased lipid-peroxidation. Plasma PCOOH roughly remained within similar levels as base lines by medication with anti-oxidant compared to that of conventional group. From these results we conclude that HD intensifies lipid peroxidation and such accumulation of hydroperoxide could account for accelerated progress of atherosclerosis in DM patients with renal insufficiency. It is worthwhile to try an administration of free radical scavenger in order to reduce PCOOH and slow down the progression of atherosclerotic vascular disease.
authors.affiliation: Kidney Center, Tokyo Women's Medical College, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sanaka
authors.forename: C
authors.initials: C
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Sanaka
authors.forename: C
authors.initials: C
authors.lastname: Higuchi
authors.forename: M
authors.initials: M
authors.lastname: Shinobe
authors.forename: Y
authors.initials: Y
authors.lastname: Hayasaka
authors.forename: T
authors.initials: T
authors.lastname: Miyazawa
authors.forename: S
authors.initials: S
authors.lastname: Ishikawa
authors.forename: H
authors.initials: H
authors.lastname: Nihei
authors.forename: Y
authors.initials: Y
authors.lastname: Omori
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000097:blood* / Q000150:complications / Q000628:therapy; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000209:etiology / Q000628:therapy; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000378:metabolism*; D006435:Renal Dialysis
chemical_list: D000975:Antioxidants; D010713:Phosphatidylcholines; C057590:phosphatidylcholine hydroperoxide